期刊文献+

血清CEA、NSE、CYFR21-1水平检测在肺癌诊断和鉴别诊断的应用价值 被引量:7

Significance of CEA,NSE and CYFR21-1 levels in serum for the diagnosis and differential diagnosis of lung cancer
下载PDF
导出
摘要 目的探讨血清CEA、NSE、CYFR21-1水平在肺癌诊断和鉴别诊断的应用价值。方法采用电化学发光法,检测102例肺癌患者、52例肺良性病变患者和30例健康体检者血清CEA、NSE、CYFR21-1水平。结果血清CEA、NSE、CYFR21-1水平与病理类型有关,CEA水平升高以肺腺癌为主,敏感性为53.49%;CYFR21-1水平升高以肺鳞癌为主,敏感性为62.85%;NSE升高以小细胞肺癌为主,敏感性为77.27%。结论 CEA联合NSE、CYFR21-1检测可提高对肺腺癌的敏感性,CYFR21-1单项或联合NSE检测可用于肺鳞癌的诊断和鉴别诊断,单纯NSE检测即对小细胞肺癌的诊断和鉴别诊断具有重要意义。 Objective To explore the significance of the detection of carcino-embryonic antigen(CEA),neurone specific enolase(NSE) and Cytokerantin-19-fragment(CYFR21-1) for the diagnosis and differential diagnosis of lung cancer.Methods 102 patients with lung cancer,52 patients with benign lung diseases and 30 healthy subjects were enrolled and detected for the serum levels of CEA,NSE and CYFR21-1 by electrochemiluminescence.Results Serum levels of CEA,NSE and CYFR21-1 serum were associated with the pathological type.High level of CEA was mainly in adenocarcinoma of lung,with sensitivity of 53.49%.Increasing of CYFR21-1 level was mainly in squamous cell carcinoma of lung,with sensitivity of 62.85%,and that of NSE levels was mainly in small cell lung cancer,with sensitivity of 77.27%.Conclusion Detection of CEA,combined with NSE and CYFR21-1 could improve the detection sensitivity of lung adenocarcinoma.Detection of CYFR21-1,alone or combined with NSE,could be used for the diagnosis and differential diagnosis of squamous cell carcinoma of lung.Single detection of NSE could be with great significance for the diagnosis and differential diagnosis of small cell lung cancer.
出处 《国际检验医学杂志》 CAS 2012年第13期1597-1598,共2页 International Journal of Laboratory Medicine
关键词 肺肿瘤 癌胚抗原 神经元特异性烯醇化酶 可溶性细胞角蛋白19片段 lung neoplasms; carcinoembryonic; neurone specific enolase; cytokerantin 19 fragment
  • 相关文献

参考文献10

二级参考文献55

  • 1毛友生,高燕宁,赫捷,张德超,程书钧.肺癌分子生物学特性与转移和预后的关系[J].中华肿瘤杂志,2006,28(8):632-634. 被引量:60
  • 2Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA Cancer J Chin,2005,55:74-108.
  • 3von Eggeling F,Davies H,Lomas L,et al.Tissue specific microdissection coupled with protein chip array technologies:applications in cancer research[J].Biotechniques,2000,29:1066-1070.
  • 4Jemal A,Tiweai RC,Murray T,et al.Cancer statistics[J].CA Cancer J Clin,2004,54:92-119.
  • 5Shitrit D,Zingerman B,Shitrit AB,et al.Diagnostic value of CYFRA 21-1,CEA,CA 19-9,CA15-3,and CA 125 assays in pleural effusions:analysis of 116 cases and review of the literature[J].Oncologist,2005,10(7):501-507.
  • 6Chen WQ Zhang SW, Zou XN. Evaluation on the incidence, mortality and tendency of lung cancer in China. Thoracic Cancer~ 2010, 1 (1): 35-40.
  • 7Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 2008, 83(5):584-594.
  • 8Mulshine JL, Sullivan DC. Clinical practice. Lung cancer screening. N Engl J Med, 2005, 353(20): 2194-2195.
  • 9Hatzakis KD, Froudarakis ME, Bouros D, et al. Prognostic value of serum tumor markers in patients with lung cancer. Respiration, 2002, 69(1): 25-29.
  • 10Greenberg AK, Lee MS. Biomarkers for lung cancer: clinical uses. Curr Opin Pulm Med, 2007, 13(4): 249-255.

共引文献103

同被引文献49

引证文献7

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部